Raymond James Financial
AUPH icon

Raymond James Financial’s Aurinia Pharmaceuticals AUPH Stock Holding History

Raymond James Financial’s Portfolio AUPH Stock Details AUPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$3.94M Buy
265,757
+33,342
+14% +$487K ﹤0.01% 2786
2025
Q4 		$3.71M Sell
232,415
-3,708
-2% -$52.6K ﹤0.01% 2747
2025
Q3 		$2.61M Sell
236,123
-965
-0.4% -$10.5K ﹤0.01% 2962
2025
Q2 		$2.01M Buy
237,088
+213,758
+916% +$1.71M ﹤0.01% 3081
2025
Q1 		$188K Sell
23,330
-595
-2% -$4.82K ﹤0.01% 4439
2024
Q4 		$215K Buy
+23,925
New +$195K ﹤0.01% 4373

Other funds holding AUPH

TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Raymond James Financial's AUPH Position: Q1 2026 in Review

Raymond James Financial increased its Aurinia Pharmaceuticals (AUPH) stake by 14% in Q1 2026, buying an estimated $487K and bringing the position to 265,757 shares worth $3.94M. The position accounts for ﹤0.01% of the portfolio, ranked #2786.

Raymond James Financial first reported a position in AUPH in Q4 2024 and has held it in 6 quarters since. 259 funds tracked by Wall St. Rank hold AUPH as of Q1 2026.

  • Raymond James Financial held 265,757 shares of Aurinia Pharmaceuticals worth $3.94M as of Q1 2026.
  • Raymond James Financial bought 33,342 Aurinia Pharmaceuticals shares in Q1 2026, an estimated $487K.
  • Aurinia Pharmaceuticals made up ﹤0.01% of Raymond James Financial's portfolio in Q1 2026, its #2786 holding.
  • Raymond James Financial first reported a position in Aurinia Pharmaceuticals in Q4 2024 and has held it in 6 quarters since.
  • 259 funds tracked by Wall St. Rank held Aurinia Pharmaceuticals as of Q1 2026.

Based on Raymond James Financial's 13F filing for Q1 2026, filed 14 May 2026.